50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Is There Value In These Growth Stocks?
MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Build A Better Tech Portfolio With Jabil Inc.
US stocks end mixed a day after Dow entered a bear market
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Autodesk Is A Mature Company Still Acting Like A Growth Stock
Leaks on Russian gas pipelines raise concerns about sabotage
NASDAQ:ARCT

Arcturus Therapeutics - ARCT Stock Forecast, Price & News

$14.16
+1.11 (+8.51%)
(As of 09/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$13.54
$14.36
50-Day Range
$13.05
$22.13
52-Week Range
$11.70
$49.96
Volume
468,300 shs
Average Volume
576,108 shs
Market Capitalization
$376.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.75

Arcturus Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
173.7% Upside
$38.75 Price Target
Short Interest
Bearish
9.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.94mentions of Arcturus Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.50) to ($2.00) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

606th out of 1,071 stocks

Pharmaceutical Preparations Industry

285th out of 531 stocks

ARCT stock logo

About Arcturus Therapeutics (NASDAQ:ARCT) Stock

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.

Receive ARCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARCT Stock News Headlines

Arcturus Therapeutics
Arcturus Therapeutics (NASDAQ:ARCT) Downgraded by StockNews.com
Friday's ETF Movers: RYT, ARKG
What 6 Analyst Ratings Have To Say About Arcturus Therapeutics
Arcturus Therapeutics Tops Q1 EPS by 338c
See More Headlines
Receive ARCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARCT Company Calendar

Last Earnings
8/09/2022
Today
9/28/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARCT
Fax
N/A
Employees
177
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$38.75
High Stock Price Forecast
$98.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+173.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
8 Analysts

Profitability

Net Income
$-203,670,000.00
Net Margins
-407.91%
Pretax Margin
-407.90%

Debt

Sales & Book Value

Annual Sales
$12.40 million
Book Value
$8.66 per share

Miscellaneous

Free Float
23,201,000
Market Cap
$376.32 million
Optionable
Optionable
Beta
2.74

Key Executives

  • Mr. Joseph E. Payne M.Sc. (Age 50)
    Founder, Pres, CEO & Director
    Comp: $960k
  • Dr. Padmanabh Chivukula (Age 43)
    Founder, Chief Scientific Officer, COO & Sec.
    Comp: $750k
  • Mr. Andrew H. Sassine MBA (Age 58)
    CFO & Director
    Comp: $750k
  • Mr. Lance Kurata
    Chief Legal Officer
  • Dr. Steven George Hughes M.B.A. (Age 54)
    M.D., Strategic Clinical Advisor & Member of Scientific Advisory Board
    Comp: $644k
  • Mr. Keith C. Kummerfeld CPA
    VP of Fin. & Corp. Controller
  • Dr. Dushyant B. Varshney Ph.D.
    Exec. VP & Chief Technology Officer
  • Mr. Deepankar Roy
    Sr. Director of Investor Relations
  • Mr. Kevin T. Skol
    Sr. VP of Bus. Devel. & Alliance Management
  • Dr. Kelly A. Lindert M.D.
    Chief Devel. Officer of Vaccines













ARCT Stock - Frequently Asked Questions

Should I buy or sell Arcturus Therapeutics stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last twelve months. There are currently 3 sell ratings, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ARCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARCT, but not buy additional shares or sell existing shares.
View ARCT analyst ratings
or view top-rated stocks.

What is Arcturus Therapeutics' stock price forecast for 2022?

8 brokerages have issued twelve-month target prices for Arcturus Therapeutics' shares. Their ARCT share price forecasts range from $8.00 to $98.00. On average, they predict the company's share price to reach $38.75 in the next year. This suggests a possible upside of 173.7% from the stock's current price.
View analysts price targets for ARCT
or view top-rated stocks among Wall Street analysts.

How have ARCT shares performed in 2022?

Arcturus Therapeutics' stock was trading at $37.01 at the beginning of 2022. Since then, ARCT shares have decreased by 61.7% and is now trading at $14.16.
View the best growth stocks for 2022 here
.

When is Arcturus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our ARCT earnings forecast
.

How were Arcturus Therapeutics' earnings last quarter?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) posted its quarterly earnings data on Tuesday, August, 9th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.90) by $1.08. The biotechnology company had revenue of $27.09 million for the quarter, compared to the consensus estimate of $3.33 million. Arcturus Therapeutics had a negative net margin of 407.91% and a negative trailing twelve-month return on equity of 78.54%. During the same quarter in the previous year, the company posted ($2.07) earnings per share.

What is Joe Payne's approval rating as Arcturus Therapeutics' CEO?

11 employees have rated Arcturus Therapeutics Chief Executive Officer Joe Payne on Glassdoor.com. Joe Payne has an approval rating of 90% among the company's employees. 70.0% of employees surveyed would recommend working at Arcturus Therapeutics to a friend.

What other stocks do shareholders of Arcturus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and Sanofi (SNY).

What is Arcturus Therapeutics' stock symbol?

Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."

Who are Arcturus Therapeutics' major shareholders?

Arcturus Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Federated Hermes Inc. (13.40%), State Street Corp (10.56%), ARK Investment Management LLC (8.72%), Sumitomo Mitsui Trust Holdings Inc. (5.44%), Nikko Asset Management Americas Inc. (5.44%) and Point72 Asset Management L.P. (3.44%). Insiders that own company stock include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Pad Chivukula and Ultragenyx Pharmaceutical Inc.
View institutional ownership trends
.

How do I buy shares of Arcturus Therapeutics?

Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcturus Therapeutics' stock price today?

One share of ARCT stock can currently be purchased for approximately $14.16.

How much money does Arcturus Therapeutics make?

Arcturus Therapeutics (NASDAQ:ARCT) has a market capitalization of $376.32 million and generates $12.40 million in revenue each year. The biotechnology company earns $-203,670,000.00 in net income (profit) each year or ($6.28) on an earnings per share basis.

How many employees does Arcturus Therapeutics have?

The company employs 177 workers across the globe.

How can I contact Arcturus Therapeutics?

Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.arcturusrx.com. The biotechnology company can be reached via phone at (858) 900-2660 or via email at ir@arcturusrx.com.

This page (NASDAQ:ARCT) was last updated on 9/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.